% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Khbach:283528,
      author       = {Kühbach, Katja and Hülsemann, Maren and Herrmann, Yvonne
                      and Kravchenko, Kateryna and Kulawik, Andreas and Linnartz,
                      Christina and Peters, Luriano and Wang, Kun and Willbold,
                      Johannes and Willbold, Dieter and Bannach, Oliver},
      title        = {{A}pplication of an {A}myloid {B}eta {O}ligomer {S}tandard
                      in the s{FIDA} {A}ssay},
      journal      = {Frontiers in neuroscience},
      volume       = {10},
      issn         = {1662-453X},
      address      = {Lausanne},
      publisher    = {Frontiers Research Foundation},
      reportid     = {FZJ-2016-01847},
      pages        = {8},
      year         = {2016},
      abstract     = {Still, there is need for significant improvements in
                      reliable and accurate diagnosis for Alzheimer's disease (AD)
                      at early stages. It is widely accepted that changes in the
                      concentration and conformation of amyloid-β (Aβ) appear
                      several years before the onset of first symptoms of
                      cognitive impairment in AD patients. Because Aβ oligomers
                      are possibly the major toxic species in AD, they are a
                      promising biomarker candidate for the early diagnosis of the
                      disease. To date, a variety of oligomer-specific assays have
                      been developed, many of them ELISAs. Here, we demonstrate
                      the sFIDA assay, a technology highly specific for Aβ
                      oligomers developed toward single particle sensitivity. By
                      spiking stabilized Aβ oligomers to buffer and to body
                      fluids from control donors, we show that the sFIDA readout
                      correlates with the applied concentration of stabilized
                      oligomers diluted in buffer, cerebrospinal fluid (CSF), and
                      blood plasma over several orders of magnitude. The lower
                      limit of detection was calculated to be 22 fM of stabilized
                      oligomers diluted in PBS, 18 fM in CSF, and 14 fM in blood
                      plasma.},
      cin          = {ICS-6},
      ddc          = {610},
      cid          = {I:(DE-Juel1)ICS-6-20110106},
      pnm          = {553 - Physical Basis of Diseases (POF3-553)},
      pid          = {G:(DE-HGF)POF3-553},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000368987300001},
      pubmed       = {pmid:26858588},
      doi          = {10.3389/fnins.2016.00008},
      url          = {https://juser.fz-juelich.de/record/283528},
}